复星医药(02196)发布前三季度业绩，归母净利润25.23亿元同比增加25.5%

智通财经2025-10-28

智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2578593592?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-28 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578593592","market":"us","top_or_hot":-1,"title":"复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361286.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-28 17:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1361286.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1361286.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1361286.html","article_id":"2578593592","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578593592","pubTimestamp":1761642749,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额及归属于上市公司股东的净利润、基本及稀释每股收益同比增加，主要系出售和睦家剩余权益以及其他非核心资产的收益贡献。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02196":"复星医药"},"translate_title":"Fosun Pharma (02196) released its results for the first three quarters, with a net profit attributable to the parent company of 2.523 billion yuan, a year-on-year increase of 25.5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额及归属于上市公司股东的净利润、基本及稀释每股收益同比增加，主要系出售和睦家剩余权益以及其他非核心资产的收益贡献。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2578593592","isCrawlerRequest":true}

复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%

精彩评论

复星医药(02196)发布前三季度业绩，归母净利润25.23亿元同比增加25.5%